In October 2023, an EU marketing authorization application (MAA) for tiratricol (Emcitate®) in the treatment of MCT8 deficiency was submitted and an application to the US FDA is anticipated soon (72). This evidence concerns the gene SLC16A2 and hyperinsulinemic hypoglycemia, familial, 4.